Nexus Drugs Private Limited

Pharmaceutical company manufacturing pellets with cGMP compliant plant and meeting regulatory requirements.

2001 | Hyderabad, Telangana (India) | Active
Last Updated:

Nexus Drugs Profile

Key Indicators

  • Authorised Capital ₹ 2.00 Cr
  • Paid Up Capital ₹ 2.00 Cr
  • Company Age 24 Year, 1 Month
  • Last Filing with ROC 31 Mar 2023
  • Open Charges ₹ 2.11 Cr
  • Revenue Growth -41.60%
  • Profit Growth 23.09%
  • Ebitda -11.00%
  • Net Worth 0.61%
  • Total Assets -11.68%

About Nexus Drugs

Nexus Drugs Private Limited (NDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 02 February 2001 and has a history of 24 years and one month. Its registered office is in Hyderabad, Telangana, India.

The Company is engaged in the Pharma Industry.

The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.

The company currently has active open charges totaling ₹2.11 Cr.

Suresh Kilaru, Ramakrishna Gadipudi, and Mallikarjun Koyilakonda serve as directors at the Company.

Company Details

  • Location

    Hyderabad, Telangana, India

  • Telephone

    +91-XXXXXXXXXX

  • Email Address

  • Website

  • Social Media

Corporate Identity Details

  • CIN/LLPIN

    U24243TG2001PTC036160

  • Company No.

    036160

  • Company Classification

    Private Limited Indian Non-Government Company

  • Incorporation Date

    02 Feb 2001

  • Date of AGM

    30 Sep 2023

  • Date of Balance Sheet

    31 Mar 2023

  • Listing Status

    Unlisted

  • ROC Code

    Roc Hyderabad

Industry

Pharma
Company report

Nexus Drugs Private Limited

Explore comprehensive data for Nexus Drugs Private Limited, including financials, compliance details, shareholding patterns, and litigation history.

Who are the key members and board of directors at Nexus Drugs?

Board Members (3)

NameDesignationAppointment DateStatus
Suresh Kilaru Country flag representing In Director 13-Aug-2020Current
Ramakrishna Gadipudi Country flag representing In Director 08-Feb-2017Current
Mallikarjun Koyilakonda Director Current

Financial Performance of Nexus Drugs.

Nexus Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 41.6% decrease. The company also saw a substantial improvement in profitability, with a 23.09% increase in profit. The company's net worth moved up by a moderate rise of 0.61%.

Nexus Drugs revenue growth over time
Nexus Drugs profit and loss trends over time
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023)YOY Growth
(FY 2022)(FY 2021)(FY 2020)(FY 2019)
Total Revenue
-41.60%
Revenue from Operations
-41.61%
Total Assets
-11.68%
Profit or Loss
23.09%
Net Worth
0.61%
EBITDA
-11.00%

What is the Ownership and Shareholding Structure of Nexus Drugs?

In 2023, Nexus Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Indicator graph

Charges (Loans)

Open Charges

₹2.11 Cr

Satisfied Charges

₹0

Charges Breakdown by Lending Institutions

  • Andhra Bank : 2.11 Cr

Latest Charge Details

DateLenderAmountStatus
14 Feb 2012Andhra Bank₹1.11 CrOpen
22 Dec 2009Andhra Bank₹1.00 CrOpen

How Many Employees Work at Nexus Drugs?

Unlock and access historical data on people associated with Nexus Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee growth trends for Nexus Drugs Private Limited

Deals i

Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Nexus Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nexus Drugs's trajectory.

Rating

Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Latest Updates, News, and FAQs on Nexus Drugs

Recent activity within the organization

  • Annual General Meeting

    Nexus Drugs Private Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records.

  • Balance Sheet

    Nexus Drugs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Hyderabad.

  • Director Appointment

    Suresh Kilaru was appointed as a Director was appointed as a Director on 13 Aug 2020 & has been associated with this company since 4 years 7 months .

  • Director Appointment

    Ramakrishna Gadipudi was appointed as a Director was appointed as a Director on 08 Feb 2017 & has been associated with this company since 8 years 1 month .

  • Charges

    A charge with Andhra Bank of Rs. 1.11 Cr registered on 14 Feb 2012 with Charge ID 10341791 was modified on 13 Dec 2013.

  • Charges

    A charge with Andhra Bank amounted to Rs. 1.11 Cr with Charge ID 10341791 was registered on 14 Feb 2012.

Frequently asked questions

  • What is the Incorporation or founding date of Nexus Drugs Private Limited?

    Nexus Drugs Private Limited was incorporated on 02 Feb 2001.

  • What is authorized share capital and paid-up capital of Nexus Drugs Private Limited?

    The authorized share capital of Nexus Drugs Private Limited is ₹ 2.00 Cr and paid-up capital is ₹ 2.00 Cr.

  • Who are the current board members & directors of Nexus Drugs Private Limited?

    Currently 3 directors are associated with Nexus Drugs Private Limited.

    • Suresh Kilaru
    • Ramakrishna Gadipudi
    • Mallikarjun Koyilakonda

  • What is the registered address of Nexus Drugs Private Limited?

    As per Ministry of Corporate Affairs (Mca), the registered address of Nexus Drugs Private Limited is Plot No 34 Flat 201 Magistic Chambers East Srinivas Nagar, S R Nagar India, Hyderabad, Telangana, 500038.

  • What is the corporate identification number (CIN) and company number of Nexus Drugs Private Limited?

    The corporate identification number (CIN) of Nexus Drugs Private Limited is U24243TG2001PTC036160 and the company number is 036160 as per Ministry of Corporate Affairs (MCA).

  • What is the official website of Nexus Drugs Private Limited?

    The Official website of Nexus Drugs Private Limited is https://www.nexusdrugs.com

  • What has been the recent revenue trend for Nexus Drugs Private Limited?

    According to the financial reports for the fiscal year 2023, the revenue trend for Nexus Drugs Private Limited has fallen by -41.60%.

  • What change has been observed in the net worth of Nexus Drugs Private Limited, and by what percentage?

    The financial reports for the fiscal year 2023 indicates that The net worth of Nexus Drugs Private Limited has experienced an upsurge of 0.61%.

  • What are the total open charges for Nexus Drugs Private Limited?

    As per the financial statements for fiscal Year 2023, The total open charges for Nexus Drugs Private Limited amount to ₹ 2.11 Cr.

  • When was the last Balance Sheet of Nexus Drugs Private Limited filed with the ROC?

    The most recent Balance Sheet for Nexus Drugs Private Limited was filed with the ROC on 31 Mar 2023.

Unlock Business Insights – Explore Instantly!

Search company & director profiles for free and gain access to critical business data.

  • 3.1M+ Companies
  • 15M+ Legal Cases
  • 525K+ Credit Ratings
  • 5.8M+ Directors & KMP
  • 750K+ Regulatory Alerts
  • 1.1M+ Companies' Financial Records
Start Free Trial

People also Viewed